Enliven Therapeutics, Inc.
USD51.73
+0.89 (+1.74%)
CEO
Richard A. Fair
IPO Date
2020-03-12
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$51.49
Prev. Close
$50.85
Day Low
$50.48
Day High
$52.00
52W Low
$14.79
52W High
$52.00
Market Cap
$3.70B
Volume
0.16M
| 1,477 |
| $45.00 |
| 24 Jun 2026 | ORBIMED ADVISORS LLC | 10 percent owner | S-Sale | Disposed | 787,024 | $45.38 |
| 24 Jun 2026 | ORBIMED ADVISORS LLC | 10 percent owner | S-Sale | Disposed | 46,776 | $45.00 |
| 22 Jun 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M-Exempt | Acquired | 6,018 | $2.48 |
| 22 Jun 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S-Sale | Disposed | 1,379 | $42.78 |
| 22 Jun 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S-Sale | Disposed | 3,401 | $43.86 |
| 22 Jun 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S-Sale | Disposed | 1,238 | $44.75 |
| 22 Jun 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M-Exempt | Disposed | 6,018 | $2.48 |
| 22 Jun 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M-Exempt | Acquired | 5,000 | $2.48 |